Skip to main content
Premium Trial:

Request an Annual Quote

Startup Cadex Genomics Raises $1.5M

NEW YORK (GenomeWeb) — Startup Cadex Genomics today announced it has raised $1.5 million in seed financing, which it will use to expand clinical studies, acquire intellectual property, and further its business plan.

The financing was led by the Redwood City, California-based firm's founders, and a group of angel investors, comprising mostly physicians. Its lead product is a blood-based assay, called Alibrex, for monitoring stage IV solid tumor cancer therapy. The test uses a routine venous blood draw and leverages PCR technology to assess whether the therapy is working within two weeks after a patient has started the regimen, allowing an oncologist to adjust the treatment, Cadex said.

The firm, founded in 2018, also announced Sudhir Sinha has joined Cadex as its chief science officer. Additionally, it named Greg Schafer its chief commercial officer, Gary Spitzer as chief medical officer, and Patrick Hall as senior vice president of medical affairs. Bill Haack is Cadex's CEO. He, Schafer, and Hall previously worked at Genomic Health to help commercialize that firm's Oncotype DX Breast assay.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.